2139 CONSIGN: An open-label phase 3B study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy. (September 2015) - Van Cutsem, E.; Ciardiello, F.; Seitz, J.F.; Hofheinz, R.D.; Verma, U.; Garcia-Carbonero, R.; Grothey, A.; Miriyala, A.; Kalmus, J.; Shapiro, J.; Falcone, A.; Zaniboni, A.